Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Septerna, Inc. (NASDAQ:SEPN) has earned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $33.8333.

SEPN has been the subject of a number of research reports. Wall Street Zen cut shares of Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. Raymond James Financial began coverage on shares of Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target for the company. Jones Trading initiated coverage on Septerna in a research note on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price for the company. HC Wainwright raised their price target on Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd.

Septerna Trading Up 4.6%

Shares of Septerna stock opened at $26.59 on Tuesday. The firm has a market capitalization of $1.19 billion, a PE ratio of -17.61 and a beta of 3.86. Septerna has a 12 month low of $4.17 and a 12 month high of $30.50. The business’s 50-day moving average price is $26.48 and its 200-day moving average price is $20.84.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). The firm had revenue of $21.50 million during the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. As a group, analysts predict that Septerna will post -7.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Septerna

Several institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC purchased a new position in shares of Septerna in the second quarter valued at about $5,723,000. VR Adviser LLC bought a new stake in shares of Septerna in the second quarter worth about $5,713,000. Millennium Management LLC lifted its holdings in Septerna by 639.6% in the 3rd quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock worth $7,227,000 after buying an additional 332,256 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Septerna by 38.9% during the third quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after buying an additional 329,264 shares during the period. Finally, Woodline Partners LP raised its holdings in shares of Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after acquiring an additional 282,585 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.